Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, Jones JR, Hockaday A, Henderson R, Cook G, Drayson MT, Jenner MW, Kaiser MF, Gregory WM, Morgan GJ, Jackson GH, Owen RG. de Tute RM, et al. Among authors: kaiser mf. J Clin Oncol. 2022 Sep 1;40(25):2889-2900. doi: 10.1200/JCO.21.02228. Epub 2022 Apr 4. J Clin Oncol. 2022. PMID: 35377708
How to use new biology to guide therapy in multiple myeloma.
Morgan GJ, Kaiser MF. Morgan GJ, et al. Among authors: kaiser mf. Hematology Am Soc Hematol Educ Program. 2012;2012:342-9. doi: 10.1182/asheducation-2012.1.342. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233602 Review.
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.
Brioli A, Boyd KD, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen R, Ross FM, Jackson GH, Cavo M, Davies FE, Morgan GJ. Brioli A, et al. Among authors: kaiser mf. Br J Haematol. 2013 Apr;161(2):291-4. doi: 10.1111/bjh.12218. Epub 2013 Jan 29. Br J Haematol. 2013. PMID: 23356460 Free article. Clinical Trial. No abstract available.
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K. Weinhold N, et al. Among authors: kaiser mf. Nat Genet. 2013 May;45(5):522-525. doi: 10.1038/ng.2583. Epub 2013 Mar 17. Nat Genet. 2013. PMID: 23502783 Free PMC article.
MMSET is the key molecular target in t(4;14) myeloma.
Mirabella F, Wu P, Wardell CP, Kaiser MF, Walker BA, Johnson DC, Morgan GJ. Mirabella F, et al. Among authors: kaiser mf. Blood Cancer J. 2013 May 3;3(5):e114. doi: 10.1038/bcj.2013.9. Blood Cancer J. 2013. PMID: 23645128 Free PMC article. No abstract available.
Improved risk stratification in myeloma using a microRNA-based classifier.
Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ. Wu P, et al. Br J Haematol. 2013 Aug;162(3):348-59. doi: 10.1111/bjh.12394. Epub 2013 May 30. Br J Haematol. 2013. PMID: 23718138 Free article.
159 results